SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting
[March 20, 2017]

Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting


SALT LAKE CITY, March 20, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company will present five scientific posters at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting in Phoenix, AZ.  The presentations will highlight new data on variant classification and hereditary cancer syndromes.

“As genetic testing for hereditary cancer syndromes increases, we are generating tremendous volumes of data and identifying new genetic variants every day.  Our highest priority is making sure patients and their families get accurate test results, which demands years of variant classification experience,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories.  “Myriad has been the leader in variant classification for more than 25 years, making us the most experienced commercial lab in the industry.  Our passion for helping patients continues, and we are very excited to be presenting five new cutting-edge studies at ACMG that advance the science of variant classification.”

The poster abstracts are now available here.  Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company.

Featured Poster Presentations

  • Title: A significant proportion of TP53 pathogenic variants detected with a hereditary pan-cancer NGS panel are somatically acquired. 
    Date: Thursday, March 23, 2017: 10:00–11:30 a.m. MST. 
    Location: Poster 173. 
    Presenter: Bradford Coffee.

  • Title: Complexities in hereditary cancer variant classification: Three case examples. 
    Date: Friday, March 24, 2017: 10:30 a.m.–12:00 p.m. MST. 
    Location: Poster 154. 
    Presenter: Erin Mundt.

  • Title: Case report: Sub-clinical Fanconi Anemia in siblings with bi-allelic BRIP1 mutations. 
    Date: Friday, March 24, 2017: 10:30 a.m.–12:00 p.m. MST. 
    Location: Poster 378. 
    Presenter: Jamie Willmott.

  • Title: Prevalence and characterization of triplications in genes associated with hereditary cancers. 
    Date: Friday, March 24, 2017: 10:30 a.m.–12:00 p.m. MST. 
    Location: Poster 148. 
    Presenter: Heather LaBreche.

  • Title: Apparent gene conversion event detected in CHEK2 using next generation sequencing analysis. 
    Date: Friday, March 24, 2017: 10:30 a.m.–12:00 p.m. MST. 
    Location: Poster 156. 
    Presenter: Shujuan Pan.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.


Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to statements related to data being presented at American College of Medical Genetics Annual Clinical Genetics Meeting; the presentation of new data highlighting variant classification and hereditary cancer syndromes; the volumes of data being generated by the Company and the daily identification of new genetic variants; and the Company’s strategic directives under the caption “About Myriad Genetics.”  These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact:
Ron Rogers 
(908) 285-0248 
rrogers@myriad.com

Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com

Primary Logo


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy